Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Renogram Study With Percutaneous Nephrolithotomy (PERC): Alterations in Renal Blood Flow as a Consequence of PERC
This study is currently recruiting participants.
Verified by Indiana Kidney Stone Institute, May 2008
Sponsored by: Indiana Kidney Stone Institute
Information provided by: Indiana Kidney Stone Institute
ClinicalTrials.gov Identifier: NCT00169741
  Purpose

Patients with large or otherwise complex renal calculi are commonly treated by percutaneous nephrolithotomy (PNL; PERC). PERC requires the creation of an approximately 10 mm channel through the renal parenchyma, into the intra-renal collecting system, in order to effect stone fragmentation and extraction. Although the nephrostomy tract is confined to a small fraction of the renal parenchyma (approximately 1%), the trauma associated with the creation of the tract will affect blood flow and oxygen delivery to regions beyond the immediate site of injury. It is possible that this could result in a significant functional renal impairment. There are several reports describing the effect of PERC on renal function, but interpretation of these studies is difficult, due to a lack of uniformity in patient selection and variability in the timing of peri-operative evaluation. Recent data from the investigators' lab, obtained from a porcine model, suggest that, acutely, PERC causes a significant decrease in renal function as measured by para amino hippurate (PAH) clearance. The purpose of this study is to determine, in a rigorous and standardized fashion, the acute effects of PERC on renal function, as measured by nuclear renography.


Condition Intervention
Renal Calculi
Other: Renogram

Drug Information available for: BaseLine
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Official Title: Alterations in Renal Blood Flow as a Consequence of Percutaneous Nephrolithotomy (PERC)

Further study details as provided by Indiana Kidney Stone Institute:

Primary Outcome Measures:
  • The hypothesis is that the effects of PERC anticipated on renal function will be largely resolved and the 6 week post-procedure study will not be significantly different from the pre-operative study. [ Time Frame: One year after study completion ] [ Designated as safety issue: No ]

Estimated Enrollment: 12
Study Start Date: May 2005
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
cohort Other: Renogram
Subjects who enroll in this study will undergo a nuclear scan called a renogram to assess renal function prior to surgery (baseline), approximately one hour after surgery (to assess percutaneous effects on renal function) and finally approximately 6 weeks post-operatively (to assess return to baseline).

Detailed Description:

PERC is a commonly used technique to treat patients harboring large or complex renal calculi. PERC is a particularly effective procedure, and has been associated with few complications. However, the effect PERC has on renal functional parameters is not well defined.

The effect of PERC on renal function has been examined in an animal model by several groups. In one porcine model, the baseline renal function, as defined by PAH and creatinine clearance, was compared to that measured at one month post-procedure. No acute data were recorded, but the authors did note that although there was no significant change in renal function at the one month follow-up point, there was a significant amount of renal scarring present. This finding of significant renal scarring following PERC in an animal model has been corroborated by others. One group has studied a canine model, and detected a significant diminution of renal function (defined by creatinine clearance) at 48 hours following PERC, and at 6 weeks following PERC renal function returned to normal. In human subjects undergoing PERC, percutaneous tracts have also been associated with renal scarring. These studies, both retrospective case series, did not capture strictly defined measures of renal function, such as creatinine clearance, but rather compared pre- and post-procedure serum creatinine as a surrogate for renal function. No significant change in serum creatinine was identified in either study, but blood collections were performed at variable times, in uncontrolled settings.

Nuclear renography is an imaging technique that records renal functional parameters. There has been only one report of nuclear renographic assessment of the effect of PERC on renal function. This report was an uncontrolled study, and the renograms were performed at a median of 22 days post-procedure. At this time interval, it is not possible to derive any conclusions regarding the acute effects of PERC on renal function.

The investigators have recently demonstrated in a porcine model that PERC is associated acutely with significant deleterious effects on renal function. Following routine PERC, glomerular filtration rate (GFR) and renal plasma flow (RPF) decline by 50% in both the treated and the untreated kidney and return to normal when measured at 72 & 74 hours (n=3 pigs). Sodium excretion, however, was markedly below baseline at 72 and 74 hours in 2 of the 3 pigs. PAH extraction, a measure of the efficiency of renal tubular secretion of organic anions, averaged 43.5 ± 9.7% and 42.6 ± 14.1% at 72 and 74 hours for the 3 pigs. These values are substantially below the baseline value of 80.4 ± 4.0% measured in sham-PNL pigs.

To date, the examination of the effect of PERC on renal function has been restricted to gross measures of function as defined by serum creatinine, and radionuclide studies performed at a sub-acute interval following PNL, often without differential measurements or controls. Importantly, the investigators' recent studies in a porcine model demonstrate that PERC may cause significant alterations in renal function. There is a need to define in a rigorous fashion the effect PERC has on renal blood flow and renal function. If a deleterious effect is identified, future efforts can be focused on minimizing this insult.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients of Methodist Urology in Indianapolis, IN
  • Age greater than 18 years
  • Ability to provide informed consent
  • Unilateral renal calculi appropriate for percutaneous removal

Exclusion Criteria:

  • Age less than 18
  • Inability to give informed consent
  • Pregnant
  • Renal calculi associated with infection
  • Serum creatinine > 1.4 mg/dL
  • Renal obstruction
  • Renal anatomic abnormality precluding accurate functional assessment using nuclear medicine techniques
  • Renal duplication/anatomic abnormality (e.g., horseshoe kidney, malrotation, ectopia, etc.)
  • Pre-existing diuretic therapy
  • Solitary functional kidney or suspected significant differential in renal function
  • Presence of diabetes, hypertension, or any other systemic disorder or medication known to affect renal function
  • History of urinary tract infection
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00169741

Contacts
Contact: Shelly Handa, RN 317-962-0870 shanda@clarian.org

Locations
United States, Indiana
Methodist Hospital Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Shelly Handa, RN     317-962-0870     shanda@clarian.org    
Principal Investigator: James E Lingeman, MD            
Sub-Investigator: Larry Munch, MD            
Sponsors and Collaborators
Indiana Kidney Stone Institute
Investigators
Principal Investigator: James E Lingeman, MD Methodist Urology, LLC
  More Information

click here to view other studies being done by Methodist Urology  This link exits the ClinicalTrials.gov site

Responsible Party: Methodist Urology ( James Lingeman )
Study ID Numbers: 05-043
Study First Received: September 9, 2005
Last Updated: May 5, 2008
ClinicalTrials.gov Identifier: NCT00169741  
Health Authority: United States: Institutional Review Board

Keywords provided by Indiana Kidney Stone Institute:
Nephrolithiasis
Renal Calculi

Study placed in the following topic categories:
Pathological Conditions, Anatomical
Urinary Calculi
Urologic Diseases
Urolithiasis
Kidney Diseases
Calculi
Nephrolithiasis
Kidney Calculi

ClinicalTrials.gov processed this record on January 13, 2009